CDK4/6 Inhibition as a Therapeutic Strategy in Breast Cancer: Palbociclib, Ribociclib, and Abemaciclib

It is estimated that about 1 in 8 US women develops invasive breast cancer during the course of their lifetime [1]. Currently in the US there are more than 3.1 million women affected by breast cancer and 40,920 American women are expected to die from breast cancer in 2018 [1,2]. Breast cancer is the most common cancer in women both in developed and developing countries. Based on global health estimates, more than 508,000 women died in 2011 from breast cancer [3]. Certainly, advancements have been made in the past few decades, and these have led to higher survival rates.
Source: Seminars in Oncology - Category: Cancer & Oncology Authors: Source Type: research